Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …

Amgen has launched an online community for European healthcare professionals, patients and carers affected by autoimmune disease immune thrombycytopenia. Styled …
NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

